HER2 Mutation-Related Tumors research hub
7 indexed studies · 6 currently recruiting
- recruitingPHASE1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This study is testing a new medicine called IAM1363 for advanced cancers with a specific change called HER2. It aims to find a safe and effective dose, including for breast, lung, and stomach cancers that have spread to the brain.
United States · France · Ireland - recruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
United States · Australia · Belgium - not yet recruiting
Immune-Marker Platform for Patients With Advanced Lung Cancer
This study looks at how your body's immune system and certain markers in your tumour relate to how well treatments work for advanced lung cancer. It helps doctors understand how to give better care.
Germany - recruitingPHASE1
Study of XB010 in Subjects With Solid Tumors
This study is testing a new medicine called XB010, both on its own and with another drug (pembrolizumab), for people with certain advanced solid cancers. It aims to see how safe it is, how well the body handles it, and if it helps shrink tumours when other treatments haven't worked.
United States · United Kingdom - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - authorisedTherapeutic exploratory (Phase II)
Phase II, clinical trial, to evaluate OS in two cohorts in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab
This study is looking at a new treatment called IMFINZI for advanced lung cancer. It wants to see if IMFINZI can help people live longer, especially those whose cancer has come back after other treatments. The study is also checking if the treatment is safe and how well it works.
Italy - recruitingPHASE1
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
This study is testing a new drug, NXP900, for people with advanced cancers like lung cancer or kidney cancer. It's a very early-stage trial to see if the drug is safe and what dose works best.
United States · United Kingdom